4 Analysts Have This to Say About SpringWorks Therapeutics
Within the last quarter, SpringWorks Therapeutics (NASDAQ:SWTX) has observed the following analyst ratings: Bullish Somewhat Bullish Indifferent Somewhat…
Benzinga’s Top Ratings Upgrades, Downgrades For December 1, 2022
Upgrades Northcoast Research upgraded the previous rating for SpartanNash Co (NASDAQ:SPTN) from Neutral to Buy. SpartanNash earned $0.55…
Applied BioMath Announces Collaboration With SpringWorks Therapeutics For Systems Pharmacology Modeling In Multiple Myeloma
Applied BioMath (www.appliedbiomath.com), the industry-leader in providing model-informed drug discovery and development (MID3) support to help accelerate and de-risk therapeutic research and development (R&D), today
Why Tuesday Morning Shares Tumbled 31%; Here Are 66 Biggest Movers From Yesterday
Gainers
NeuroBo Pharmaceuticals, Inc. (NASDAQ: NRBO) jumped 101.3% to settle at $0.5558 on Monday after the company announced a 1-for-30 reverse stock split.
NIO, Lucid Group And Other Big Gainers From Monday
U.S. stocks closed higher with the Dow Jones surging more than 200 points on Monday. Here is the list of some big stocks moving higher in the previous session.
SpringWorks Shares Pop After Expanded Multiple Myeloma Pact With GSK
SpringWorks Therapeutics Inc (NASDAQ:SWTX) has entered into an expanded global, non-exclusive license and collaboration agreement with GSK plc (NYSE:GSK) for SpringWorks’ nirogacestat with…
SpringWorks Therapeutics Announces $225M Private Placement Financing
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that it has
SpringWorks Therapeutics Announces Late-Breaking Oral Presentation of Phase 3 DeFi Data at the European Society for Medical Oncology (ESMO) Congress 2022
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, today announced that data from the
Why Invitae Climbed Around 279%; Here Are 98 Biggest Movers From Yesterday
Gainers
Invitae Corporation (NYSE: NVTA) surged 278.5% to close at $8.63 after the company reported better-than-expected Q2 EPS.
Why Plug Power Is Trading Higher By Around 14%, Here Are 73 Stocks Moving In Wednesday’s Mid-Day Session
Gainers
BioAtla, Inc. (NASDAQ: BCAB) gained 50.1% to $5.42 following Q2 results.
Euro Tech Holdings Company Limited (NASDAQ: CLWT) surged 39.5% to $2.0380.